Transaction Date | Recipient | Shares | Type | Price | Value |
---|---|---|---|---|---|
15th December 2020 | Davis Jerel | 9,497 | Other acquisition or disposition | $0.00 | |
15th December 2020 | Davis Jerel | 285,217 | Other acquisition or disposition | $0.00 | |
15th December 2020 | Davis Jerel | 21,707 | Other acquisition or disposition | $0.00 | |
15th December 2020 | Davis Jerel | 8,579 | Other acquisition or disposition | $0.00 | |
9th December 2020 | Eric Dobmeier | 2,000 | Open or private purchase | $13.08 | $26,150.00 |
8th December 2020 | Eric Dobmeier | 2,000 | Open or private purchase | $13.24 | $26,483.40 |
23rd November 2020 | Srinivas Akkaraju | 500,000 | Grant/award etc. | $10.00 | $5,000,000.00 |
11th November 2020 | Eric Dobmeier | 2,500 | Open or private purchase | $13.75 | $34,375.00 |
10th November 2020 | Eric Dobmeier | 2,000 | Open or private purchase | $13.86 | $27,720.00 |
5th October 2020 | Eric Dobmeier | 46,337 | Grant/award etc. | $0.00 |
Based on disclosure changes, sentiment, insider trading and news impact we give a rating of 4/10.
Aduro BioTech, Inc. is a clinical-stage immunotherapy company. Its technology platforms include STING Pathway Activator, B-select monoclonal antibody, and LADD. The company's platforms stimulate and/or regulate innate and adaptive immune responses.
6th November 2020
6th November 2020
6th November 2020